Walvax Biotechnology Co., Ltd. (SHE: 300142)
China
· Delayed Price · Currency is CNY
13.03
0.00 (0.00%)
Dec 18, 2024, 3:04 PM CST
Walvax Biotechnology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Operating Revenue | 3,089 | 4,106 | 5,079 | 3,452 | 2,927 | 1,102 | Upgrade
|
Other Revenue | 7.92 | 7.92 | 7.65 | 10.5 | 11.62 | 19.69 | Upgrade
|
Revenue | 3,097 | 4,114 | 5,086 | 3,463 | 2,939 | 1,121 | Upgrade
|
Revenue Growth (YoY) | -31.76% | -19.12% | 46.89% | 17.82% | 162.13% | 28.24% | Upgrade
|
Cost of Revenue | 740.12 | 750.76 | 673.14 | 403.54 | 404.53 | 235.2 | Upgrade
|
Gross Profit | 2,357 | 3,363 | 4,413 | 3,059 | 2,534 | 886.02 | Upgrade
|
Selling, General & Admin | 1,405 | 1,829 | 2,302 | 1,636 | 1,352 | 675.77 | Upgrade
|
Research & Development | 621.16 | 763.49 | 922.25 | 616.36 | 173.78 | 63.06 | Upgrade
|
Other Operating Expenses | 50.66 | -3.76 | 16.48 | 19.83 | -8.34 | -8.89 | Upgrade
|
Operating Expenses | 2,009 | 2,628 | 3,239 | 2,267 | 1,511 | 714.54 | Upgrade
|
Operating Income | 348.36 | 734.81 | 1,174 | 792.22 | 1,024 | 171.48 | Upgrade
|
Interest Expense | -9.87 | -5.95 | -7.11 | -5.77 | -0.6 | -30.56 | Upgrade
|
Interest & Investment Income | 73.5 | 81.35 | 81.82 | 103.29 | 42.83 | 42.57 | Upgrade
|
Currency Exchange Gain (Loss) | 3.06 | 3.06 | 0.82 | -0.22 | -4.65 | -0.44 | Upgrade
|
Other Non Operating Income (Expenses) | -96.05 | -49.15 | -75.39 | 33.88 | 39.57 | 36.7 | Upgrade
|
EBT Excluding Unusual Items | 319.01 | 764.11 | 1,174 | 923.4 | 1,101 | 219.75 | Upgrade
|
Gain (Loss) on Sale of Investments | -261.05 | -234.75 | -199.33 | -280.74 | 279.89 | 13.7 | Upgrade
|
Gain (Loss) on Sale of Assets | -0.36 | -0.83 | -0.38 | 0.23 | -1.08 | -0.03 | Upgrade
|
Asset Writedown | -96.95 | -11.31 | -1.66 | -5.11 | -6.6 | -3.96 | Upgrade
|
Other Unusual Items | 237.9 | 81.75 | 97.8 | 71.15 | - | - | Upgrade
|
Pretax Income | 198.54 | 598.98 | 1,070 | 708.95 | 1,373 | 229.46 | Upgrade
|
Income Tax Expense | 33.81 | 87.65 | 132.24 | 107.59 | 162.12 | 35.33 | Upgrade
|
Earnings From Continuing Operations | 164.74 | 511.33 | 938.23 | 601.35 | 1,211 | 194.14 | Upgrade
|
Net Income to Company | 164.74 | 511.33 | 938.23 | 601.35 | 1,211 | 194.14 | Upgrade
|
Minority Interest in Earnings | -42.36 | -91.93 | -209.57 | -173.6 | -208 | -52.16 | Upgrade
|
Net Income | 122.37 | 419.39 | 728.65 | 427.75 | 1,003 | 141.97 | Upgrade
|
Net Income to Common | 122.37 | 419.39 | 728.65 | 427.75 | 1,003 | 141.97 | Upgrade
|
Net Income Growth | -83.70% | -42.44% | 70.35% | -57.36% | 606.60% | -86.43% | Upgrade
|
Shares Outstanding (Basic) | 1,599 | 1,600 | 1,603 | 1,569 | 1,539 | 1,538 | Upgrade
|
Shares Outstanding (Diluted) | 1,599 | 1,600 | 1,604 | 1,573 | 1,559 | 1,538 | Upgrade
|
Shares Change (YoY) | -1.45% | -0.21% | 1.93% | 0.90% | 1.37% | 0.05% | Upgrade
|
EPS (Basic) | 0.08 | 0.26 | 0.45 | 0.27 | 0.65 | 0.09 | Upgrade
|
EPS (Diluted) | 0.08 | 0.26 | 0.45 | 0.27 | 0.64 | 0.09 | Upgrade
|
EPS Growth | -83.46% | -42.32% | 67.12% | -57.74% | 597.07% | -86.44% | Upgrade
|
Free Cash Flow | 162.83 | 188.25 | 110.31 | -398.21 | -292.94 | -289.81 | Upgrade
|
Free Cash Flow Per Share | 0.10 | 0.12 | 0.07 | -0.25 | -0.19 | -0.19 | Upgrade
|
Dividend Per Share | 0.010 | 0.010 | 0.010 | 0.027 | 0.070 | - | Upgrade
|
Dividend Growth | 0% | 0% | -62.96% | -61.43% | - | - | Upgrade
|
Gross Margin | 76.10% | 81.75% | 86.77% | 88.35% | 86.24% | 79.02% | Upgrade
|
Operating Margin | 11.25% | 17.86% | 23.08% | 22.88% | 34.84% | 15.29% | Upgrade
|
Profit Margin | 3.95% | 10.19% | 14.33% | 12.35% | 34.13% | 12.66% | Upgrade
|
Free Cash Flow Margin | 5.26% | 4.58% | 2.17% | -11.50% | -9.97% | -25.85% | Upgrade
|
EBITDA | 669.52 | 1,025 | 1,422 | 927.65 | 1,148 | 248.11 | Upgrade
|
EBITDA Margin | 21.62% | 24.91% | 27.96% | 26.79% | 39.06% | 22.13% | Upgrade
|
D&A For EBITDA | 321.15 | 289.97 | 248.4 | 135.43 | 123.95 | 76.63 | Upgrade
|
EBIT | 348.36 | 734.81 | 1,174 | 792.22 | 1,024 | 171.48 | Upgrade
|
EBIT Margin | 11.25% | 17.86% | 23.08% | 22.88% | 34.84% | 15.29% | Upgrade
|
Effective Tax Rate | 17.03% | 14.63% | 12.35% | 15.18% | 11.80% | 15.39% | Upgrade
|
Revenue as Reported | 3,097 | 4,114 | 5,086 | - | - | - | Upgrade
|
Advertising Expenses | - | 78.01 | 94.83 | 24.15 | 20.85 | 4.22 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.